Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT)

American Heart Journal

Volumn 140, Issue 4, 2000, Pages 631-636

  Chesney, C M ^a   Elam, M B ^a   Herd, J A ^a   Davis, K B ^a   Garg, R ^a   Hunninghake, D ^a   Kennedy, J W ^a   Applegate, W B ^a  

^a BAPTIST MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; NICOTINIC ACID; PROTHROMBIN; VON WILLEBRAND FACTOR; WARFARIN;

AGED; ARTERY DISEASE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033809508     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.109648     Document Type: Article

References (32)

1. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study
2. Association of hemostatic factors with peripheral vascular disease
3. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study
4. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients
5. Coagulation parameters in peripheral arterial disease (PAD)
6. A 6-year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
7. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states
8. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses
9. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation Investigators
10. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: Design and pilot study
11. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study
12. The prevalence of peripheral arterial disease in a defined population
13. Indirect systolic pressures and pulse waves in arterial occlusive disease of the lower extremities
14. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation
15. On the role of vitamin C and other antioxidants n atherogenesis and vascular dysfunction
16. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia
17. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers
18. Fibrinogen and cardiovascular disease
19. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
20. Fibrinogen and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and haemostasis
21. Fibrinogen is a predictor of mortality in coronary heart disease patients
22. A 6-year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
23. Influence of smoking and plasma factors on patency of femoro-popliteal graft thrombosis
24. Influences of lipid-modifying agents on hemostasis
25. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease
26. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids: The Oxford Cholesterol Study Group
27. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
28. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
29. Long-term effects of pravastatin on plasma concentration of C-reactive protein
30. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-kinding globulin
31. Niacin induced clotting factor synthesis deficiency with coagulopathy
32. Clofibrate and niacin in coronary heart disease